FOR IMMEDIATE RELEASE
Oncolytics Biotech ® Inc. Announces Start of Enrolment
in U.S. Phase 2 Melanoma Cancer Clinical Trial
CALGARY, AB, --- September 24, 2009 - Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC,
NASDAQ:ONCY) announced today that the Cancer Therapy & Research Center at the University of Texas
Health Science Center (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous
administration of REOLYSIN ® in combination with paclitaxel and carboplatin in patients with metastatic
melanoma. The Principal Investigator is Dr. Devalingam Mahalingam, M.D., Ph.D., MRCP(UK), MRCP(I),
clinical investigator in GI/thoracic oncology and drug development at the CTRC.
“We have seen some very encouraging results in our clinical trials using REOLYSIN in combination with other
therapies in metastatic melanoma patients,” said Dr. Brad Thompson, President and CEO of Oncolytics. “For
example, of nine evaluable melanoma patients treated intravenously in our combination REOLYSIN and
chemotherapy trials, five had stable disease or better (two partial responses and three stable disease).
“In our local administration REOLYSIN and radiation studies, all of the evaluable melanoma patients (10) had
stable disease or better in the target lesion, (three partial responses, one significant minor response and six stable
disease). These results, combined with preclinical work demonstrating that in vivo combination treatment
resulted in markedly reduced tumour growth compared to single agent treatments, provided the rationale for our
collaborators to explore a Phase 2 combination study for patients with metastatic melanoma.”
“Today, few effective treatment options exist for patients with advanced malignant melanoma,” said Dr.
Mahalingam. “We welcome this collaboration with Oncolytics, and are excited to have started patient enrolment